Royalty Pharma Plc (RPRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Royalty Pharma Plc (RPRX) has a cash flow conversion efficiency ratio of 0.077x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($760.54 Million) by net assets ($9.94 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Royalty Pharma Plc for the company's overall valuation and market capitalisation.
Royalty Pharma Plc - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Royalty Pharma Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Royalty Pharma Plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Royalty Pharma Plc ranked by their cash flow conversion efficiency. Explore earnings quality score of Royalty Pharma Plc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China State Construction Engineering Corp Ltd
SHG:601668
|
0.033x |
|
Avenue Supermarts Limited
NSE:DMART
|
0.057x |
|
Cincinnati Financial Corporation
NASDAQ:CINF
|
0.042x |
|
Synchrony Financial
NYSE:SYF
|
0.146x |
|
SUMITOMO EL.IND.ADR
F:SMO1
|
N/A |
|
KONE Oyj
HE:KNEBV
|
0.129x |
|
NARI Technology Co Ltd
SHG:600406
|
0.034x |
|
Hexagon AB (publ)
ST:HEXA-B
|
0.054x |
Annual Cash Flow Conversion Efficiency for Royalty Pharma Plc (2002–2025)
The table below shows the annual cash flow conversion efficiency of Royalty Pharma Plc from 2002 to 2025. View RPRX share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $9.71 Billion | $2.49 Billion | 0.256x | -4.27% |
| 2024-12-31 | $10.34 Billion | $2.77 Billion | 0.268x | -9.64% |
| 2023-12-31 | $10.08 Billion | $2.99 Billion | 0.296x | +31.63% |
| 2022-12-31 | $9.53 Billion | $2.14 Billion | 0.225x | +14.34% |
| 2021-12-31 | $10.25 Billion | $2.02 Billion | 0.197x | +44.87% |
| 2020-12-31 | $14.97 Billion | $2.03 Billion | 0.136x | -49.94% |
| 2019-12-31 | $6.14 Billion | $1.67 Billion | 0.271x | -23.64% |
| 2018-12-31 | $4.55 Billion | $1.62 Billion | 0.356x | +12.03% |
| 2017-12-31 | $4.47 Billion | $1.42 Billion | 0.317x | +9183.95% |
| 2016-12-31 | $4.46 Billion | $-15.58 Million | -0.003x | +35.22% |
| 2015-12-31 | $4.70 Billion | $-25.33 Million | -0.005x | +99.19% |
| 2014-12-31 | $44.02 Million | $-29.33 Million | -0.666x | -240.37% |
| 2003-12-31 | $23.49 Million | $11.15 Million | 0.475x | +50.95% |
| 2002-12-31 | $26.85 Million | $8.45 Million | 0.315x | -- |
About Royalty Pharma Plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabe… Read more